ProQuest Associates IV’s Agile Therapeutics AGRX Stock Holding History

ProQuest Associates IV’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1.85M	Hold	2,531	–	–	3.5%	4
2018 Q2	$2.5M	Hold	2,531	–	–	3.85%	4
2018 Q1	$13M	Hold	2,531	–	–	14.96%	3
2017 Q4	$13.6M	Hold	2,531	–	–	18.09%	3
2017 Q3	$22.6M	Hold	2,531	–	–	22.62%	2
2017 Q2	$19M	Hold	2,531	–	–	24.27%	3
2017 Q1	$16.3M	Hold	2,531	–	–	4.89%	2
2016 Q4	$28.9M	Hold	2,531	–	–	8.17%	2
2016 Q3	$35.3M	Hold	2,531	–	–	9.73%	2
2016 Q2	$38.5M	Hold	2,531	–	–	15.67%	2
2016 Q1	$31.4M	Buy	2,531 +197	+8%	+$2.54M	12.21%	2
2015 Q4	$45.6M	Hold	2,334	–	–	8.79%	2
2015 Q3	$31.5M	Hold	2,334	–	–	7.45%	2
2015 Q2	$40.1M	Hold	2,334	–	–	8.24%	3
2015 Q1	$43.3M	Buy	2,334 +406	+21%	+$7.12M	14.12%	3
2014 Q4	$23.7M	Buy	+1,928	New	+$24.5M	12%	3

Other funds holding AGRX

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

ProQuest Associates IV's AGRX Position: Q3 2018 in Review

ProQuest Associates IV held its Agile Therapeutics (AGRX) position steady in Q3 2018 at 2,531 shares worth $1.85M. The position accounts for 3.5% of the portfolio, ranked #4.

ProQuest Associates IV first reported a position in AGRX in Q4 2014 and has held it in 16 quarters since. The position peaked at $45.6M in Q4 2015. 29 funds tracked by Wall St. Rank hold AGRX as of Q3 2018.

ProQuest Associates IV held 2,531 shares of Agile Therapeutics worth $1.85M as of Q3 2018.
ProQuest Associates IV left its Agile Therapeutics share count unchanged in Q3 2018.
Agile Therapeutics made up 3.5% of ProQuest Associates IV's portfolio in Q3 2018, its #4 holding.
ProQuest Associates IV first reported a position in Agile Therapeutics in Q4 2014 and has held it in 16 quarters since.
ProQuest Associates IV's Agile Therapeutics position peaked at $45.6M in Q4 2015.
29 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2018.

Based on ProQuest Associates IV's 13F filing for Q3 2018, filed 14 Nov 2018.